Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.

Literature DB >> 29545338

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.

Laurens E Franssen¹, Inger S Nijhof¹, Suzana Couto², Mark-David Levin³, Gerard M J Bos⁴, Annemiek Broijl⁵, Saskia K Klein⁶, Yan Ren², Maria Wang², Harry R Koene⁷, Andries C Bloem⁸, Aart Beeker⁹, Laura M Faber¹⁰, Ellen van der Spek¹¹, Reinier Raymakers¹², Roos J Leguit¹³, Pieter Sonneveld⁵, Sonja Zweegman¹, Henk Lokhorst¹, Tuna Mutis¹, Anjan Thakurta¹⁴, Xiaozhong Qian¹⁴, Niels W C J van de Donk¹⁵.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2018 PMID： 29545338 PMCID： PMC6068039 DOI： 10.3324/haematol.2017.186601

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

13 in total

1. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

Authors: Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; Laura A Bruins; Jessica E Schmidt; Scott Van Wier; Xiu-Bao Chang; Chad C Bjorklund; Rafael Fonseca; P Leif Bergsagel; Robert Z Orlowski; A Keith Stewart
Journal: Blood Date: 2011-08-22 Impact factor: 22.113

2. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

Authors: Annemiek Broyl; Rowan Kuiper; Mark van Duin; Bronno van der Holt; Laila el Jarari; Uta Bertsch; Sonja Zweegman; Arjan Buijs; Dirk Hose; Henk M Lokhorst; Hartmut Goldschmidt; Pieter Sonneveld
Journal: Blood Date: 2012-12-11 Impact factor: 22.113

3. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.

Authors: Inger S Nijhof; Laurens E Franssen; Mark-David Levin; Gerard M J Bos; Annemiek Broijl; Saskia K Klein; Harry R Koene; Andries C Bloem; Aart Beeker; Laura M Faber; Ellen van der Spek; Paula F Ypma; Reinier Raymakers; Dick-Johan van Spronsen; Peter E Westerweel; Rimke Oostvogels; Jeroen van Velzen; Berris van Kessel; Tuna Mutis; Pieter Sonneveld; Sonja Zweegman; Henk M Lokhorst; Niels W C J van de Donk
Journal: Blood Date: 2016-09-19 Impact factor: 22.113

4. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.

Authors: François Ghiringhelli; Cedric Menard; Pierre Emmanuel Puig; Sylvain Ladoire; Stephan Roux; François Martin; Eric Solary; Axel Le Cesne; Laurence Zitvogel; Bruno Chauffert
Journal: Cancer Immunol Immunother Date: 2006-09-08 Impact factor: 6.968

5. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors: Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal: Science Date: 2013-11-29 Impact factor: 47.728

6. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Authors: K Martin Kortüm; Elias K Mai; Nur H Hanafiah; Chang-Xi Shi; Yuan-Xiao Zhu; Laura Bruins; Santiago Barrio; Patrick Jedlowski; Maximilian Merz; Jing Xu; Robert A Stewart; Mindaugas Andrulis; Anna Jauch; Jens Hillengass; Hartmut Goldschmidt; P Leif Bergsagel; Esteban Braggio; A Keith Stewart; Marc S Raab
Journal: Blood Date: 2016-07-25 Impact factor: 22.113

7. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Authors: Ruth Eichner; Michael Heider; Vanesa Fernández-Sáiz; Frauke van Bebber; Anne-Kathrin Garz; Simone Lemeer; Martina Rudelius; Bianca-Sabrina Targosz; Laura Jacobs; Anna-Maria Knorn; Jolanta Slawska; Uwe Platzbecker; Ulrich Germing; Christian Langer; Stefan Knop; Herrmann Einsele; Christian Peschel; Christian Haass; Ulrich Keller; Bettina Schmid; Katharina S Götze; Bernhard Kuster; Florian Bassermann
Journal: Nat Med Date: 2016-06-13 Impact factor: 53.440

8. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Authors: A Lopez-Girona; D Mendy; T Ito; K Miller; A K Gandhi; J Kang; S Karasawa; G Carmel; P Jackson; M Abbasian; A Mahmoudi; B Cathers; E Rychak; S Gaidarova; R Chen; P H Schafer; H Handa; T O Daniel; J F Evans; R Chopra
Journal: Leukemia Date: 2012-05-03 Impact factor: 11.528

9. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.

Authors: Konstantinos Dimopoulos; Alexandra Søgaard Helbo; Helga Fibiger Munch-Petersen; Lene Sjö; Jesper Christensen; Lasse Sommer Kristensen; Fazila Asmar; Niels Emil Ulrich Hermansen; Casey O'Connel; Peter Gimsing; Gangning Liang; Kirsten Grønbaek
Journal: Mol Oncol Date: 2017-12-30 Impact factor: 6.603

10. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors: Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal: Science Date: 2013-11-29 Impact factor: 47.728

17 in total

Review 1. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Authors: Max Jan; Adam S Sperling; Benjamin L Ebert
Journal: Nat Rev Clin Oncol Date: 2021-03-02 Impact factor: 66.675

2. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.

Authors: Adam S Sperling; Michael Burgess; Hasmik Keshishian; Jessica A Gasser; Shruti Bhatt; Max Jan; Mikołaj Słabicki; Rob S Sellar; Emma C Fink; Peter G Miller; Brian J Liddicoat; Quinlan L Sievers; Rohan Sharma; Dylan N Adams; Elyse A Olesinski; Mariateresa Fulciniti; Namrata D Udeshi; Eric Kuhn; Anthony Letai; Nikhil C Munshi; Steven A Carr; Benjamin L Ebert
Journal: Blood Date: 2019-05-01 Impact factor: 25.476

3. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.

Authors: Sarah Gooding; Naser Ansari-Pour; Fadi Towfic; María Ortiz Estévez; Philip P Chamberlain; Kao-Tai Tsai; Erin Flynt; Marissa Hirst; Dan Rozelle; Paula Dhiman; Paola Neri; Karthik Ramasamy; Nizar Bahlis; Paresh Vyas; Anjan Thakurta
Journal: Blood Date: 2021-01-14 Impact factor: 25.476

4. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.

Authors: Yuan Xiao Zhu; Chang-Xin Shi; Laura A Bruins; Xuewei Wang; Daniel L Riggs; Brooke Porter; Jonathan M Ahmann; Cecilia Bonolo de Campos; Esteban Braggio; P Leif Bergsagel; A Keith Stewart
Journal: Blood Cancer J Date: 2019-02-11 Impact factor: 11.037

5. Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Authors: Phoebe A Huang; Shaunna L Beedie; Cindy H Chau; David J Venzon; Sheryl Gere; Dickran Kazandjian; Neha Korde; Sham Mailankody; Ola Landgren; William D Figg
Journal: Sci Rep Date: 2019-10-16 Impact factor: 4.379

Review 6. Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma.

Authors: Dawn Swan; Mark Gurney; Janusz Krawczyk; Aideen E Ryan; Michael O'Dwyer
Journal: Hemasphere Date: 2020-04-03

7. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.

Authors: Mitsuhito Hirano; Yoichi Imai; Yuta Kaito; Takahiko Murayama; Kota Sato; Tadao Ishida; Junichi Yamamoto; Takumi Ito; Muneyoshi Futami; Masaki Ri; Hiroshi Yasui; Tamami Denda; Yukihisa Tanaka; Yasunori Ota; Masanori Nojima; Yasuhiko Kamikubo; Noriko Gotoh; Shinsuke Iida; Hiroshi Handa; Arinobu Tojo
Journal: J Exp Clin Cancer Res Date: 2021-03-23

8. Cereblon enhancer methylation and IMiD resistance in multiple myeloma.

Authors: Larissa Haertle; Santiago Barrio; Umair Munawar; Seungbin Han; Xiang Zhou; Cornelia Vogt; Rafael Alonso Fernández; Max Bittrich; Yanira Ruiz-Heredia; Matteo Da Viá; Josip Zovko; Andoni Garitano-Trojaola; Niccolò Bolli; Anna Ruckdeschel; Thorsten Stühmer; Manik Chatterjee; Miriam Kull; Jan Krönke; Xabier Agirre; Jose I Martin-Subero; Peter Raab; Hermann Einsele; Leo Rasche; Joaquin Martinez-Lopez; Thomas Haaf; K Martin Kortüm
Journal: Blood Date: 2021-11-04 Impact factor: 22.113

9. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.

Authors: Alessandra Di Bacco; Nizar J Bahlis; Nikhil C Munshi; Hervé Avet-Loiseau; Tamás Masszi; Luísa Viterbo; Ludek Pour; Peter Ganly; Michele Cavo; Christian Langer; Shaji K Kumar; S Vincent Rajkumar; Jonathan J Keats; Deborah Berg; Jianchang Lin; Bin Li; Sunita Badola; Lei Shen; Jacob Zhang; Dixie-Lee Esseltine; Katarina Luptakova; Helgi van de Velde; Paul G Richardson; Philippe Moreau
Journal: Eur J Haematol Date: 2020-04-15 Impact factor: 2.997

10. Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.

Authors: Laurens E Franssen; Inger S Nijhof; Chad C Bjorklund; Hsiling Chiu; Ruud Doorn; Jeroen van Velzen; Maarten Emmelot; Berris van Kessel; Mark-David Levin; Gerard M J Bos; Annemiek Broijl; Saskia K Klein; Harry R Koene; Andries C Bloem; Aart Beeker; Laura M Faber; Ellen van der Spek; Reinier Raymakers; Pieter Sonneveld; Sonja Zweegman; Henk M Lokhorst; Anjan Thakurta; Xiaozhong Qian; Tuna Mutis; Niels W C J van de Donk
Journal: Oncotarget Date: 2018-09-21